Fundraising Fox

Neuraptive

Louisville, US · Founded 2017 · 2 known investors

Find your way into Neuraptive

Neuraptive is a biotechnology company staffed by professionals with expertise in research and development, manufacturing, and commercialization in the pharmaceutical industry.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

DJ
David JacksonNamed on SEC filing
GD
Gino DiSciulloNamed on SEC filing
RH
Randy HubbellNamed on SEC filing

Board

GP
Greg ParekhBoard directorFounder and Managing Partner at New Rhein Healthcare Investors, LLC
IGIvan Gergel
Ivan GergelinDirector Board of DirectorsManaging Partner and Chief Medical Officer at New Rhein Healthcare Investors, LLC

Investors · 2

New Rhein Healthcare Investors, LLC✓ verifiedPhiladelphiavia Ivan Gergel · board
Central Texas Angel NetworkAustin

Reported raises · per SEC filings

Form D private placements

$29.8M disclosed across 4 rounds · 2017–2022

▶$19.5MraisedOct 2022 · 71 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Randy HubbellDirector
  • Robert S RadieExecutive Officer, Director
  • Greg ParekhDirector
  • David PierceDirector
  • Ivan GergelDirector
  • David JacksonDirector
  • Evan TzanisExecutive Officer
Offering amount
$38.1M
Amount sold
$19.5M
Minimum investment
$25K
Sales commissions
$1.1M
Placement agents
Maxim Group LLC
First sale
Sep 2022
Incorporated
Corporation, Pennsylvania
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.2MraisedApr 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David JacksonExecutive Officer, Director
  • Gino DiSciulloDirector
  • Greg ParekhDirector
  • Ivan GergelDirector
  • Randy HubbellDirector
Offering amount
$12.5M
Amount sold
$10.2M
First sale
Dec 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David M JacksonExecutive Officer, Director
Offering amount
$100K
Amount sold
$100K
Minimum investment
$100K
First sale
Aug 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25KraisedAug 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David M. JacksonExecutive Officer
Offering amount
$1M
Amount sold
$25K
Minimum investment
$10K
First sale
Jul 2017
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Neuraptive - New Rhein Healthcare Investorsnewrhein.com · Feb 2025Lab Notes: Proscia raises $9M from investors; Neuraptive gets orphan drug designation for experimental tech - Philadelphia Business Journalbizjournals.com · Jan 2024Neuraptive Therapeutics Raises $11.5M in Series A Funding - FinSMEsfinsmes.com · Dec 2018Neuraptive Therapeutics, Inc., a biotech startup based in Colorado and Pennsylvania, raised $11.5 million in a Series A funding round led by New Rhein Healthcare Investors LLCprnewswire.com · Dec 2018

Frequently asked questions

What does Neuraptive do?
Neuraptive is a biotechnology company staffed by professionals with expertise in research and development, manufacturing, and commercialization in the pharmaceutical industry.
Who are Neuraptive's investors?
Neuraptive's investors include New Rhein Healthcare Investors, LLC, Central Texas Angel Network.
How much funding has Neuraptive raised?
Neuraptive has disclosed $29.8M raised across 4 rounds.
Where is Neuraptive headquartered?
Neuraptive is headquartered in Louisville, US.